Bioelectric Therapeutics: The Next Multi-Trillion-Dollar Healthcare Revolution

“What excites me is that this behaves like a platform, not a single product. The same engine, pointed at different problems.”

— Erik A. Nilsen, PhD, Co-founder & Chief Technology Officer

Step back from any single device and the shape of a field comes into view. Bioelectric medicine, at its core, is the targeted modulation of the body's electrical pathways using precision instruments that can both sense and stimulate. Stated that plainly, it sounds narrow. In practice it reaches across pain, infection, cancer, and neurology — anywhere electrical signaling shapes how the body works or fails.

Several forces are pushing this from the margins toward the mainstream at the same time. The opioid crisis created urgent demand for effective therapies that are not addictive. Patients increasingly want non-invasive options they can use at home rather than only in a clinic. And the enabling technologies — digital health, low-power sensors, and AI — have finally matured enough to make adaptive devices practical.

Why a platform changes the economics

Here is the part I care about most as a CEO. Traditional drug development is slow, expensive, and largely one-shot: a compound either works for an indication or it does not. Modular bioelectric hardware behaves more like digital technology. You can iterate it, update its software, and re-point the same underlying engine at a new problem. That changes the economics of innovation — it lets a company learn faster and spread the cost of that learning across many applications.

A futuristic medical-technology interface. “Platforms win when the underlying signal is universal. Bioelectricity is that signal, and it spans nearly every system in the body.”

— Erik A. Nilsen, PhD, Co-founder & Chief Technology Officer

The application map is genuinely broad. Pain and inflammation are the flagship near-term programs. Infection and wound healing are close behind. Cancer and neurology are longer-horizon frontiers. None of these are guarantees, and I would distrust anyone who pretended otherwise. But the breadth is the point: a platform that can serve several of these areas is far more resilient than a single bet.

Building for scale and for trust

Electrome's foundation is a platform with a Knowledge Graph at its center and personalization tools around it, designed for scalable deployment rather than boutique, one-off treatments. The vision is to expand from the flagship pain and wound programs into chronic disease, oncology, transplantation, and trauma over time.

“A category this large is built one disciplined milestone at a time. The science sets the ceiling; execution sets the pace.”

— Wanni Davis, PhD, MBA, Chief Operating Officer

Scale, though, is meaningless without trust. The same modularity that lets us move fast obligates us to move responsibly — with real evidence, honest labeling, and respect for the clinicians and patients who will decide whether any of this earns a place in care. That is the standard by which I want this company judged.

A clinician reviews digital health data on a tablet.